Defining Myasthenia Gravis: From Symptoms to Pathophysiology

Myasthenia gravis (MG), derived from Greek words meaning 'grave muscle weakness,' is a B cell-mediated autoimmune disease primarily targeting postsynaptic acetylcholine receptors (AChR) at the neuromuscular junction. This disrupts signal transmission, causing fatigable weakness exacerbated by activity and improved by rest.

Symptoms typically begin with ocular involvement—ptosis (drooping eyelids) and diplopia (double vision)—progressing to generalized MG in 85% of cases, affecting bulbar (speech/swallowing), limb, and respiratory muscles. Myasthenic crisis, a life-threatening respiratory failure, occurs in 10-20% of patients, often triggered by infection or medication.

In the UK, the Association of British Neurologists (ABN) 2025 guidelines recommend initial symptomatic treatment with acetylcholinesterase inhibitors like pyridostigmine, followed by immunosuppressants such as corticosteroids, azathioprine, or mycophenolate mofetil. Thymectomy benefits AChR-positive patients under 65. Newer therapies include complement inhibitors (eculizumab, ravulizumab), FcRn blockers (efgartigimod), and rituximab for refractory cases.

Despite advances, refractory MG—defined as failure of ≥2 immunosuppressants at adequate doses for ≥12 months, with persistent symptoms or crises—remains challenging, consuming significant NHS resources.

The Refractory Challenge: Why Standard Therapies Fail

Refractory MG patients endure uncontrolled symptoms, frequent crises (up to 5x higher hospitalization rates), and polypharmacy side effects. UK data indicate refractory patients account for disproportionate healthcare use, with costs 3-5 times higher than responsive cases.

Prior to this study, no biomarkers predicted refractoriness. Therapies like rituximab deplete CD20+ B cells but spare long-lived plasma cells producing pathogenic AChR antibodies, explaining partial responses.

Patient stories underscore the burden: one UK advocate described 10 years of misdiagnosis and crises before refractory confirmation, highlighting diagnostic delays averaging 1-2 years.

Study Methodology: Unraveling the Immune Puzzle

Led by Dr. Madhvi Menon (UKRI Future Leaders Fellow) and involving Dr. Katy Dodd (Manchester Centre for Clinical Neuroscience), the team performed multi-parameter flow cytometry on peripheral blood mononuclear cells (PBMCs) from 100+ participants.

• Cohorts: 20 refractory MG, 40 stable immunosuppressed, 20 stable non-immunosuppressed, 20 treatment-naive, 30 healthy controls—all AChR Ab+.
• Phenotyping: B/T cell subsets (memory B cells, Tregs via FoxP3/CD25), myeloid cells (DCs, monocytes), complement receptors (CD21/35/55/46/59).
• Functional assays: Cytokine production (IL-6, TNF-α, IL-10) post-TLR/CD40 stimulation.
• Proteomics: Circulating complement (C3/C5/clusterin) via ELISA.
• Rituximab subset: 10 refractory patients monitored 13 months post-therapy for B cell reconstitution and clinical scores (QMG, MG-ADL).
• Analysis: PCA/k-means clustering identified refractory-enriched profiles.

This rigorous approach yielded robust, reproducible signatures.

Key Discoveries: The Distinct Immune Signature

Refractory MG patients exhibited:

• Adaptive immunity: Highest memory B cell (CD27+) frequency (up to 40% vs 20% controls), class-switched memory bias, pro-inflammatory cytokine burst (IL-6/TNF-α 2-3x higher post-stimulation).
• Regulatory deficit: Tregs reduced 50% (correlating inversely with severity/QoL), fewer DCs.
• Innate changes: Expanded classical monocytes, elevated NK cells.
• Complement hyperactivity: Circulating C3/C5/clusterin 1.5-2x higher; upregulated receptors (CD55/CD46 on T cells, CD21 on B cells). CD55 blockade cut TNF-α in CD4 T cells.

Unsupervised clustering segregated refractory patients, with top markers: memory B cells, naive T cells, CD55+ CD8 T cells.

Biomarkers for Personalized Therapy Prediction

The study nominates actionable biomarkers:

• Memory B cell frequency >30% / Treg <5% predict refractoriness.
• C3/C5/clusterin levels correlate with MG-ADL scores.
• Baseline B cells <3% forecast rituximab non-response (persistent plasmablasts).

Post-rituximab, responders depleted B cells fully; non-responders retained plasmablasts, high complement, CD55+ T cells—suggesting plasma cell/complement targeting (e.g., BCMA CAR-T, ravulizumab).

Therapeutic Horizons: Targeting Plasma Cells and Complement

Findings endorse:

• Plasma cell depletion (anti-CD19/CD38/BCMA).
• IL-6 blockade (satralizumab).
• Complement inhibitors (expanding eculizumab use).
• Treg therapies (IL-2 low-dose, antigen-specific).

ABN guidelines may incorporate these for refractory stratification. Ongoing UK trials (e.g., rituximab biosimilars) align with precision immunology.

Spotlight on Researchers and Lydia Becker Institute

Dr. Madhvi Menon, expert in B cell immunology, led analysis: “This signature advances prediction and personalization.” Dr. Katy Dodd, clinician, noted frustration for refractory patients.

The Lydia Becker Institute drives immunology innovation, fostering PhD/postdoc roles in autoimmunity. Explore research jobs at Manchester.

Patient Impact and NHS Implications

For UK's 2,000+ refractory patients, biomarkers could halve ineffective trials, cutting hospitalizations (5x higher). Personalized care aligns with NHS Long Term Plan, reducing £millions in crises.

Stories like 10-year diagnostic odysseys underscore urgency; this research offers hope via targeted trials.

Future Directions: Trials and Immunology Careers

Prospective validation, multi-omics integration, and rituximab/complement combo trials loom. Manchester plans longitudinal cohorts.

In higher ed, immunology booms; craft your CV for roles like Menon's. UKRI funds postdocs; check postdoc positions.

Photo by Denis Sebastian Tamas on Unsplash

Conclusion: A Step Toward Curing Refractory MG

Manchester's immune signature discovery transforms refractory MG management, from biomarkers to novel targets. Patients gain predictability; researchers, new avenues. Stay informed via higher ed news; explore Rate My Professor, higher ed jobs, career advice.